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Abbreviation Full term/phrase 
CRC Colorectal cancer 
NS Noonan syndrome 
FAP Familial adenomatous polyposis 
HNPCC Hereditary non-polyposis colorectal cancer 
NF1 Neurofibromatosis 1 
MUTYH Mut Y DNA glycosylase gene 
KRAS KRAS proto-oncogene, GTPase 
BRAF B-RAF proto-oncogene serine/threonine 
kinase 
NRAS NRAS proto-oncogene 
MLH1 DNA mismatch repair protein Mlh1 
MSH2 DNA mismatch repair protein Msh2 
MSH6 DNA mismatch repair protein Msh6 
PMS2 Mismatch repair endonuclease PMS2 
WES Whole exome sequencing 
NCOR1 Nuclear receptor corepressor 1 gene 
TP53 Tumor protein p53 gene 
SOS1 Ras/Rac guanine nucleotide exchange factor 
1 gene 
APC adenomatosis polyposis coli, WNT signaling 
pathway regulator gene 
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Abstract 
Noonan syndrome (NS) is a developmental syndrome caused by germline mutations in the 
Ras signaling pathway. No association has been shown between NS and pediatric colorectal 
cancer (CRC). We report the case of CRC in a pediatric patient with NS. The patient 
underwent whole genome sequencing. A germline SOS1 mutation c.1310T>C (p. Ile437Thr) 
confirmed NS diagnosis. No known hereditary cancer syndromes were identified. Tumor 
analysis revealed two mutations: a TP53 missense mutation c.481G>A (p. Ala161Tyr) and 
NCOR1 nonsense mutation c.6052C>T (p. Arg2018*). This report highlights the complexity 
of Ras signaling and the interplay between developmental syndromes and cancer. 
 
 
Introduction 
Noonan syndrome (NS) is a developmental syndrome with an estimated prevalence of 1 
in 1000-2500 and characterized by craniofacial abnormalities, cardiac defects, and cognitive 
delay.1 NS is caused by germline mutations affecting the Ras signaling pathway, as are 
neurofibromatosis 1 (NF1) and several other syndromes that are collectively referred to as 
Rasopathies.2  
The Ras signaling pathway is a ubiquitous intracellular signaling pathway that has been 
shown to play a central role in the pathogenesis of adult colorectal cancer (CRC). 
Interestingly, Rasopathies carry an inconsistent cancer predisposition ranging from an 
elevated risk of neurologic-type tumors in children with NF1 to a mild, almost exclusive risk 
for hematologic malignancies in Noonan syndrome patients of all ages. 3-5 Germline 
mutations affecting Ras signaling pathway proteins have not been reported to carry a 
predisposition to colorectal cancer. Only 3 cases of Noonan syndrome patients with 
colorectal cancer have ever been reported and none in the pediatric population. 3 
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Many of the same somatically mutated genes identified to cause adult CRC have been 
shown to be mutated in the germline of several cancer-predisposition syndromes. However, 
these syndromes account for the minority of pediatric CRC cases. 6,7 Here we report the first 
report of pediatric colorectal cancer in a Noonan syndrome patient and the first whole-
genome analysis of pediatric colorectal cancer. 
 
Clinical Course and Methods  
A 14 year old female with Noonan syndrome presented with a four week history of 
nausea, vomiting, abdominal pain, and persistent constipation. CT of the abdomen and 
pelvis, and barium enema demonstrated complete large bowel obstruction with transition 
point at the sigmoid colon (Supplemental Figure S1). The patient was admitted, 
sigmoidoscopy revealed the site of the obstruction to be 35 cm from the anus, and then 
taken to the operating room. Exploratory laparotomy revealed an obstructing colonic mass in 
the sigmoid colon that was resected. Lymph nodes and observed omental and pelvic 
peritoneal lesions were biopsied. A diverting end-colostomy was made.  
Pathology of the surgical specimens showed colon adenocarcinoma, stage T4aN2aM1 
with low grade differentiation. Lymphovascular and perineural invasion was seen. Several 
lymph nodes (4 of 29) were positive for disease, three with extracapsular 
extension.  Metastatic adenocarcinoma was observed in the omentum and in a pelvic 
peritoneal lesions.  
Initial genetic testing for the three major known types of inherited colorectal cancer 
found no mutations associated with mismatch repair, APC, or MUTYH genes. BRAF V600 
mutation and NRAS extended analyses were also negative. A KRAS gene mutation 
(c.38G>A) was present in the colonic mass, a contraindication to EGFR inhibitor therapy. 
The patient was then enrolled in PEDS-MI-ONCOSEQ, a prospective integrative clinical 
sequencing that has been approved by our institutional review board. 8 The patient’s parents 
provided informed consent and received mandatory pre-enrollment genetic counseling.  
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Specifics of the PEDS-MI-ONCOSEQ sequencing procedure and bioinformatics 
analyses have been described previously (Supplemental Material S1).8 Nucleic acid 
preparation and high-throughput sequencing were performed using standard the Clinical 
Laboratory Improvement Amendments (CLIA) protocols. Pathogenicity of germline variants 
was determined through a review of the published literature and databases. 
The patient received induction chemotherapy with 6 cycles of folinic acid (400 mg/m2), 5-
fluorouracil (400 mg/m2, then 2400 mg/m2 over 46 hours), and oxaliplatin (85 mg/m2) 
combination chemotherapy with bevacizumab (5 mg/kg).  Chemotherapy was administered 
every 2 weeks. Oxaliplatin was discontinued after 6 cycles.  CT scans of the neck, chest, 
abdomen, and pelvis showed no evidence of metastasis. 
The patient continued a maintenance chemotherapy regimen of folinic acid, 5-
fluorouracil, and bevacizumab every two weeks and did not receive radiation therapy. The 
patient relapsed at cycle 37, presenting with a small bowel obstruction, renal insufficiency 
and bilateral hydronephrosis.  CT and PET imaging suggested progression of disease 
corresponding to these site of the pelvic lesion and suspected disease in Hartmann’s pouch, 
uterine wall and bladder wall.  The small bowel obstruction resolved and the hydronephrosis 
improved with the placement of bilateral ureteral stents.  The family declined biopsy. The 
patient was treated with irinotecan 180 mg/m2 every 2 weeks and palliative measures to 
maximize quality of life. The patient received 3 doses of irinotecan, but despite a lack of 
irinotecan induced diarrhea the patient began experiencing worsening symptoms of ileus. At 
time of manuscript submission, the patient was managed in hospice care. 
 
Results and Discussion 
Integrative clinical sequencing revealed 3 mutations with clinical significance, one in the 
germline and two somatic mutations in the tumor sample  (Table 1). Four somatic point 
mutations were also identified in the tumor sample (Supplemental Table S1). No CNV focal 
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amplification or deletions detected, somatic insertion/deletion mutations, driving gene 
fusions, outlier expressions, or pathogens were detected. 
SOS1 is an important Ras pathway regulator as a guanine nucleotide exchange factor 
(GEF). A SOS1 missense mutation c.1310T>C (p. Ile437Thr) was identified in the germline, 
inducing an amino acid substitution (I437Y) near the plekstrin homology domain (aa 444-
548) (Supplemental Figure S2).  This mutation has been previously reported as pathogenic 
for Noonan syndrome.9 Of note, SOS1 loss of heterozygosity was also demonstrated in the 
tumor. Despite playing an important role in Ras signaling, SOS1 has been shown to be 
insignificant in the development of cancer. 10 
p53, the protein product of TP53, has a well described importance in tumor 
suppression, with more than half of all sporadic human cancers demonstrating p53 
mutations. 11 A TP53 missense mutation c.481G>A (p. Ala161Tyr) was identified in the 
tumor. This induces an amino acid substitution (A161Y) within the DNA-binding domain (aa 
102-292) (Supplemental Figure S2). More than 80% of TP53 mutations in human tumors 
localize to the DNA-binding domain. 12 Of note, germline TP53 mutations cause Li-Fraumeni 
syndrome (LFS) which carries a very high susceptibility to cancer. However, LFS is present 
in only 1.3% of early onset CRC cases. 12,13 
 NCOR1 is the cornerstone of an epigenetic complex that affects cell differentiation in 
several cell types via modulation of chromatin histone deacetylation.14 A NCOR1 somatic 
nonsense mutation c.6052C>T (p. Arg2018*) was identified, causing significant protein 
truncation (Supplemental Figure S2). The C-terminal end of NCOR1 contains two separate 
nuclear receptor-interacting domains, ID1 (aa 2032-2115) and ID2 (aa 2212-2273). Motifs 
within these regions have been shown to be necessary for binding to nuclear hormone 
receptors. NCOR1 also plays an important role in acute promyelocytic leukemia therapy. 
Retinoic acid competes with NCOR1 for transcription factor RAR alpha binding. 15 Recently 
large scale genomic studies have identified NCOR1 driver mutations in breast cancer and 
hepatocarcinoma. 16,17 
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Of note, no mutations affecting the Wnt signaling pathway were identified in the 
germline or the tumor. The Wnt pathway plays an important pathogenic role in CRC, with 
93% of all CRC tumors contain mutations affecting this pathway. 6,11 Germline mutations in 
this pathway cause hereditary colorectal cancer syndromes including familial adenomatous 
polyposis (FAP) and juvenile polyposis.  
 The genetics of developmental syndromes have offered important insight into cancer, 
and the overlapping manifestations been described as a continuous spectrum (Figure 1). 
6,7,18,19 Variations in genotype likely disrupt development by affecting the interplay between 
different signal transduction and epigenetic pathways. Subsequent compensation may 
explain survival as well as non-intuitive cancer risks. 2,18-20  With the advancement of genetic 
testing and tissue pipelines, future whole-genome studies could identify the pathway 
changes of therapeutic value. 
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Table 1. Clinically significant mutations identified from genome-wide analysis 
Three point mutations with clinical significance were identified, one germline mutation and 
two somatic mutations in the tumor sample. The germline mutation in SOS1 and somatic 
mutation in TP53 encoded missense mutations causing a single amino acid change in the 
protein product. The somatic mutation in NCOR1 encoded a nonsense mutation causing a 
truncation of the protein product. 
Gene Variant type Genome 
locus 
Exon Nucleotide 
change 
Amino 
acid 
change  
Normal 
protein 
function 
 
Clinical 
significance 
SOS1 Germline 2p22.1 10 T1310C Ile437Thr Guanine 
exchange 
factor, Ras 
signaling 
 
Diagnostic 
mutation for 
Noonan 
syndrome 24 
TP53 Somatic 17p13.1 4 G481A Ala161Tyr Tumor 
suppressor 
> 80% of 
TP53 
mutations in 
human 
tumors 
localize to the 
DNA binding 
domain. 22 
NCOR1 Somatic 17p11.2 39 C6052T Arg2018* Transcriptio
nal 
coregulator
y protein  
 
ID1 domain 
dictates 
retinoic acid 
sensitivity in 
APL 31  
NCOR 1 
mutations 
may predict 
tamoxifen 
resistance in 
breast cancer 
45 
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Figure 1. Overlap of developmental disease and cancer. A continuous clinical spectrum has been 
hypothesized to link genetic developmental syndromes and cancer predisposition, with 
developmental phenotypes possibly reflecting compensatory signaling changes. With permission 
from Bellacosa 2013, AJMG.  
 
 
 
